1. Strategic Cooperation Achievements
Signed a Long-term Supply Agreement for Pyridine Intermediates with India's Sun Pharmaceutical: Tailored to the needs of Sun Pharma's anti-infective drug production, supplied high-purity 2-chloropyridine and 3-aminopyridine with an annual supply volume of 2,500 tons and a contract value of 15 million US dollars. Leveraging China-India cross-border logistics corridors, achieved weekly cargo shipments, shortening the delivery cycle by 18 days compared with traditional routes, and became one of Sun Pharma's key Asian suppliers for pyridine series intermediates.
Co-built a GMP-compliant Warehousing & Distribution Center with Singapore's DKSH: Invested 4 million US dollars to establish a temperature-controlled warehousing facility in Singapore, specializing in the storage and distribution of moisture-sensitive pharmaceutical intermediates. Serving over 15 pharmaceutical manufacturers in Indonesia, Malaysia and the Philippines, the localized delivery ratio reached 35% that year, improving small-batch order fulfillment efficiency by 40%.
2. Export Scale Cases
Export of Aromatic Amine Intermediates to Southeast Asia: Exported p-nitroaniline, o-toluidine and other basic pharmaceutical intermediates to Vietnam, Thailand and Myanmar, with an annual export volume of 6,000 tons and an export value of 58 million RMB, achieving a year-on-year growth of 32%. The products meet BP/USP standards, supporting local generic drug production and helping reduce raw material costs by 12%-15% for partner enterprises.
Aliphatic Acid Intermediates Exported to Africa: Covering 7 countries including South Africa, Kenya and Nigeria, the annual export volume reached 4,200 tons with an export value of 41 million RMB. By adopting vacuum packaging and sea-air combined transportation, the product qualification rate during transportation reached 99.8%, making the company a leading Asian supplier in Africa's generic drug intermediate market.
3. Market Breakthrough Cases
First Entry into the European Generic Drug Market: Para-hydroxybenzoic acid intermediates passed EU GMP certification and EDQM quality inspection, successfully entering the supply chain of generic drug manufacturers in Spain and Portugal with an annual export volume of 900 tons, filling the gap in the company's high-standard pharmaceutical intermediate exports to Europe.
Cross-border RMB Settlement for Pharmaceutical Exports: In response to exchange rate volatility risks, promoted RMB settlement among customers in Russia, Turkey and Bangladesh, adding 12 new RMB-settled customers that year with a cumulative settlement amount exceeding 95 million RMB.
Jun 13, 26
Analyzing Oxandrolone Side Effects and Selective Peptides
Understanding the nuances of pharmaceutical interactions and potential oxandrolone side effects is critical for researchers and clinicians aiming to optimize patient outcomes in metabolic and cardiovascular studies. While many chemical compounds offer profound therapeutic potential, the ability to distinguish between intended biological activity and adverse reactions ensures a higher standard of safety and efficacy in translational medicine. On a global scale, the demand for high-purity research peptides and active pharmaceutical ingredients has surged as scientific communities seek to mitigate the risks associated with legacy treatments.
Jun 12, 26
Clinical Guide to Oxandrolone Uses and Metabolic Benefits
In the contemporary landscape of metabolic medicine and pharmaceutical research, understanding the diverse oxandrolone uses is pivotal for clinicians and researchers alike. While the industry continues to evolve, the demand for high-purity active pharmaceutical ingredients APIs remains the cornerstone of effective therapeutic outcomes, particularly in treating muscle wasting and metabolic dysfunction. The global shift toward personalized medicine has highlighted the importance of specific androgenic agents and GLP-1 agonists in managing complex patient profiles. By analyzing the systemic impact of these compounds, the pharmaceutical sector can better address the needs of patients recovering from severe trauma or managing chronic endocrine imbalances.
Jun 11, 26
Salmon Calcitonin and oxandrolone use for Bone Health
The global pharmaceutical landscape is increasingly focusing on the precision of bone metabolism regulation, where the strategic oxandrolone use is often discussed in the context of anabolic recovery, yet the specialized application of Salmon Calcitonin provides a critical alternative for systemic calcium management. Understanding the nuanced differences between anabolic agents and calcitonin-based therapies is essential for healthcare providers aiming to treat severe osteoporosis and hypercalcemia. In the realm of chemical raw material manufacturing, the production of high-purity peptides like Salmon Calcitonin represents a pinnacle of biotechnological achievement. While some research focuses on oxandrolone use for muscle wasting, Salmon Calcitonin targets the osteoclast directly,
Contact Us
Professional Chemical Supply, Efficient Service
Subscribe For Newsletter!
Your Email...
